If you are taking cholinesterase inhibitors and/or memantine you will not qualify for the Dimebon Connection study. However, there is another Dimebon clinical trial that has these inclusion criteria:
- Diagnosis of Alzheimer's Disease.
- MMSE 12-26 inclusive.
- If on existing anti-dementia therapy, have been on a stable dose of anti-dementia therapy (cholinesterase inhibitors and/or memantine) for at least 60 days prior to dosing in study.
- If not taking existing anti-dementia therapy, have not received therapy with cholinesterase inhibitors and/or memantine within 60 days prior to dosing in this study.
Popular articles on the Alzheimer's Reading Room
- Worried About Alzheimer's? The Holy Grail of Exercise
- The Metamorphosis of This Alzheimer's Caregiver (Part One)
- Test Your Memory (TYM) for Alzheimer's or Dementia in Five Minutes
- Does the Combination of Aricept and Namenda Help Slow the Rate of Decline in Alzheimer's Patients
- Five Ways to Keep Alzheimer's Away
- Is it Really Alzheimer's or Something Else?
- Alzheimer's Wandering Why it Happens and What to Do
- 50 Good Reasons to Subscribe to the Alzheimer's Reading Room Now
- World Health Care Spending and Performance Ranking by Country (Table)
- What is Dementia?
- Dementia and the Eight Types of Dementia
- Walmart and this Alzheimer's Caregiver
- Dimebon Connection Study
- Are Alzheimer's Caregivers the Forgotten?
- A Simple Three Minute Test Can Detect the Earliest Stage of Alzheimer's Disease
- Wii a Useful Tool for Alzheimer's Caregivers
- 2009 Alzheimer's Disease Facts and Figures
- The Mini-Cog Test for Alzheimer's and Dementia
Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. The Alzheimer's Reading Room is the number one website on the Internet for news, advice, and insight into Alzheimer's disease. Bob has written more than 800 articles with more than 18,000 links on the Internet. Bob resides in Delray Beach, FL.
Original content Bob DeMarco, Alzheimer's Reading Room